SWOG clinical trial number
C10403
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)
Closed
Phase
Abbreviated Title
Phase II Adolescent/Young Adult with Untreated ALL
Status Notes
Permanent Closure Effective 9/14/12
Activated
01/15/2008
Closed
09/14/2012
Participants
Research committees
Leukemia
Treatment
Cytosine Arabinoside
Cyclophosphamide
Dexamethasone
Vincristine
6-Mercaptopurine
6-Thioguanine
Allopurinol
Daunomycin
Doxorubicin
Leucovorin Calcium
Methotrexate
Trimethoprim sulfa
PEG-L-Asparaginase
Eligibility Criteria Expand/Collapse
Newly diagnosed ALL with B or T-precursor. Pts with Burkitt type leukemia not eligible. 16 to 29 years (inclusive). 0-2 performance status. Pts with Down Syndrome not eligible. No prior therapy for ALL except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava dyndrome or renal failure due to leukemic infiltration of kidneys. Single-dose intrathecal cytarabine allowed. (Chemo must begin within 72 hours of dose). Prior steroid therapy allowed but must be documented.
Publication Information Expand/Collapse
2023
PMid: PMID36269846 | PMC number: PMC9841239
2022
2021
PMid: PMID33496745 | PMC number: PMC7839367
PMid: PMID33785862 | PMC number: PMC8257494
2019
PMid: PMID30658992 | PMC number: PMC6450431
2017
PMid: PMID27618250 | PMC number: PMC5320866
2008
Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths -- more rationale for the CALBG-WSOG-ECOG C10403 trial based on COG AALL0232
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A042001
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
Accrual
47%
Open
Phase
SWOG Clinical Trial Number
CTSU/AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
Research Committee(s)
Leukemia
Activated
12/04/2020
Open